Zydus Cadila has received the final approval from the USFDA to market Ranolazine Extended-
Release Tablets (US RLD Ranexa®), 500 mg and 1.000 mg. The drug is used to treat chronic
angina and may be used with other medicines that are used for heart problems and blood
pressure control. It will be manufactured at the group's formulations manufacturing facility
at Baddi.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
